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ABSTRACT 
Objective: The purpose of this study was to ascertain the applicability of degradable materials for fabrication of an insulin release system.  
Methods: Insulin implants were prepared by using poly (vinyl alcohol) (PVA), gellan and chitosan by solution casting method. The prepared 
implants were evaluated for swellability, content uniformity, potency and purity of insulin in implants, scanning electron microscopy studies, in 
vitro release studies, in vitro degradation studies using lysozyme, stability studies and circular dichroism spectroscopy. 
Results: The swelling degree of the implants was found to be in the range of 1.07-1.56. The diffusion coefficient of water through the implant was 
found to depend on the calcium chloride (CaCl2) concentration. The diffusion coefficient of insulin through the chitosan-PVA-gellan in the early 
stages was found to be in the range of 1.99×10-5 cm2/sec to 5.24×10-5 cm2/sec and at later stages in the range of 6.9×10-6 cm2/sec to 1.10×10-5 
cm2/sec. The weight of the implants was 48±0.58 mg. The insulin content in the implants was 9.86±0.10 mg. The potency of insulin extracted from 
the implants was 27.11±0.75 U/mg or 95.12±2.61 % of the control insulin. The in vitro release studies showed that insulin was released completely 
in a period of 13-19 d depending on the composition of the implant. The increase in CaCl2 
Conclusion: These studies provide validity for the potential utility of chitosan-PVA-gellan implant systems for the delivery of insulin. The studies 
also demonstrate that insulin maintained its integrity within the implant system. Implants showed the complete release of insulin in 19 d and the 
release of insulin from the implants depended on the amount of CaCl
retarded the rate of insulin release whereas the increase 
in PVA content leads to the rapid release of insulin. The device was found to undergo significant weight loss due to enzyme mediated degradation.  
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Diabetes mellitus refers to a group of metabolic diseases characterised 
by chronic hyperglycemia, due to defects in insulin secretion. The 
treatment of diabetes by insulin injection provides only a poor 
approximation of normal glucose homoeostasis, especially for insulin-
dependent diabetes where blood glucose concentrations vary widely 
despite insulin therapy [1, 2]. This is because the pharmacokinetics of 
insulin following subcutaneous injection does not match the profiles of 
physiological insulin secretion [3, 4]. Moreover, subcutaneous 
injections result in localized insulin deposits that lead to local 
hypertrophy and fat deposits under the skin. Together these 
disadvantages lead to suboptimal pharmacodynamics properties of 
the applied insulin, which does not allow mimicking the complex 
physiological insulin secretion pattern [5]. 
Polymeric implants are one of the promising devices for protein drug 
delivery. Some polymeric matrices can protect drugs from 
physiological conditions that could degrade the proteins. Therefore, a 
lot of research is ongoing to identify appropriate polymer systems to 
formulate ideal protein drug delivery systems that would allow ease of 
incorporation of protein drugs without affecting their bioactivity, 
deliver them at the desired rate and exhibit biocompatibility when in 
contact with the tissue [6]. Gellan is an anionic polysaccharide of 
microbial origin, which is capable of forming a three-dimensional 
network by complexation with cations and hydrogen bonding with 
water. The apparent viscosity of gellan gum dispersions can be 
markedly increased by increasing both pH and cation concentration 
[7]. Furthermore, its ingestion has never produced reported adverse 
dietary, physiological or toxic effects in animals and humans. These 
properties make this polysaccharide suitable for several commercial 
applications, such as in the food industry and in drug delivery [8]. 
While gellan gum has never been used to deliver biologically active 
macromolecules, it has some potential for this application. The ion-
induced cross-linking property of gellan avoids the presence of 
initiator or organic cross-linker that can be toxic to the protein activity 
if not removed from the device. The preparation also does not need to 
involve organic solvents and/or high temperatures that could 
denature the protein. Polyvinyl alcohol (PVA) is one of the hydrogels 
often used in biomedical applications [9]. It is a water-soluble 
synthetic polymer with excellent film forming, emulsifying and 
adhesive properties. Chitosan forms a polyionic complex with gellan 
and this property was used in the current work to prepare an insulin 
implant of chitosan-PVA-gellan for maintenance of prolonged 
therapeutic levels of insulin.  
The objective of this investigation was to develop a chitosan-PVA-
gellan implant device as an implant for insulin delivery. The 
procedure for the preparation of chitosan-PVA-gellan implant was 
optimized. The swelling index and in vitro release characteristics for 
drug delivery were investigated. 
MATERIALS AND METHODS 
Materials  
Gellan, polyvinyl alcohol (average molecular weight range 1,20,000–
1,80,000 and degree of hydrolysis 99%), Chitosan (medium 
molecular weight, 75-85% deacetylated), insulin (porcine pancreas) 
were purchased from Sigma, St. Louis, MO, USA. Lysozyme (HiMedia 
50,000 U/mg), Calcium chloride (CaCl2
Preparation of chitosan-PVA-gellan insulin implant 
), potassium dihydrogen 
phosphate, sodium hydroxide and sodium chloride were obtained 
from SISCO Scientific Laboratories, Mumbai India. 
The compositions of various formulations are given in table 1. A 
0.5% w/v chitosan solution in 0.2 M acetic acid was poured into a 
glass mold (Area 28.3 cm2) and dried at 25 °C under vacuum for 48 
h. PVA was dissolved in water by heating to 90 °C, to which gellan 
and glycerin (2% v/v) were added and stirred until a clear solution 
was obtained. To this solution, insulin dissolved in small volume of 
0.1 N HCl and diluted with pH 7.4 phosphate buffered saline (PBS) 
was added at 25 °C and stirred gently [9]. The solution was then 
poured over the chitosan film in a glass mould and dried at 25 °C 
under vacuum for 24 h. Over this layer 10 ml of 0.5%, w/v of 
chitosan was poured and was allowed to dry at 25 °C under vacuum. 
The dry formulations were cut into 10 mm circular discs. 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 9, Issue 3, 2017 
Satish  
Int J App Pharm, Vol 9, Issue 3, 2017, 37-41 
 
38 
Table 1: The composition of various formulations 
Ingredients F-I F-II F-III F-IV 
Gellan (% w/v) 1  1  1  1 
Poly(vinyl alcohol) (% w/v) 3  3 6  6 
Glycerin (mL) 3  3  3  3  
CaCl2 0.05 (%w/v) 0.1  0.05 0.1 
Distilled water (mL) 20 20 20 20 
 
Content uniformity, potency and purity of insulin in implants 
Content uniformity and insulin potency in the implants was 
determined by an RP-HPLC method (Shimadzu LC 10 AD, Japan). 
The implants were reduced to small pieces and placed in 20 ml of 
0.05 N HCl for 24 h and filtered using Whatman filter paper. From 
this 0.1 ml was pipetted out into a 10 ml standard volumetric flask 
and made up to the volume with 0.05 N HCl and assayed for drug 
content by reversed-phase high-performance liquid chromate-
graphy method (RP-HPLC). The RP-HPLC consisted of the C-18 
column; the mobile phase was 0.2 M sodium sulphate (pH 2.3) and 
acetonitrile in the ratio of 74:26. The flow rate was 1 ml/min and the 
insulin was detected using UV detector at 214 nm [10].  





Where Cu is the potency of the unknown, Cs:  is standard potency, 
Ru:  peak area of unknown and Rs:  
Swelling studies 
peak area of the standard [11]. 
Implants were placed in a glass beaker containing 50 ml of 
phosphate buffered saline (PBS, pH 7.4) and the beakers were 
placed in a shaking incubator at 37 °C and 100 rpm. The implants 
were weighed periodically throughout the experiment. The swelling 
process was characterised by the swollen weight ratio (q=Ws/Wd), 
where Ws is the weight of the swollen implant and Wd
where A and k
 is the weight 
of the initial dry implant. The swelling studies were carried out in 
triplicate. The Berens–Hopfenberg equation [12] was fitted to the 
data obtained from the swelling studies. 
Mt
M∞
= {1 − A exp(K2t)} (1) 
2 are constants calculated from the slopes and 
intercepts of the plot of log(1-Mt/M∞) versus time t at times later 
than those corresponding to Mt/M∞=0.6. The equation Mt/M∞= ktn 
adequately describing a major portion of the swelling behaviour fails 
to give an accurate analysis above Mt/M∞
Scanning electron microscopy studies 
=0.6. To obtain a better 
model after 60%, we have used Berens–Hopfenberg equation. 
The surface morphology of dried implants was determined using a 
scanning electron microscope (JEOL 6320). The implant samples 
were mounted on a base plate and coated with gold using a vapour 
deposition technique. The surface was then scanned at 
magnifications of 500× and 1000×.  
In vitro release studies 
The implant was placed in 100 ml glass beaker containing 50 ml of 
PBS (pH 7.4). The beaker was placed in a shaking incubator at 37 °C 
and 100 rpm. The samples were withdrawn every 24 h and the 
insulin concentration was determined using RP-HPLC. The in vitro 
release studies were carried out until the complete release of insulin 
was observed. 
Mathematical analysis of water uptake and drug release 
Analysis of the swelling behaviour of implants in PBS at pH 7.4 was 









 𝑓𝑓𝑓𝑓𝑓𝑓 0.4 < 𝑀𝑀𝑡𝑡/𝑀𝑀∞ < 1 (2) 
Where D is the water diffusion coefficient, δ the half thickness of the 
implant, Mt the amount of water uptake at the time, t and M∞
Where D is the insulin diffusion coefficient, δ the half thickness of 
the implant, M
 is the 
water uptake at equilibrium [13]. Diffusion coefficients of insulin 






)  𝑓𝑓𝑓𝑓𝑓𝑓 0.4 < 𝑀𝑀𝑡𝑡/𝑀𝑀∞ < 1 (2) 
t the amount of insulin released at the time, t and M∞  
is the amount of insulin in the implant. Equation 3 was used to 
calculate the diffusion coefficient of insulin at early stages when the 
fraction of insulin released (Mt/M∞) was less than 0.6 and for later 
stages equation 2 was used when the fraction of insulin released 
(Mt/M∞) was greater than 0.6. This is because plotting with 
equations 2 and 3 fits the experimental data well until Mt/M∞
Enzyme-mediated degradation studies 
<0.6.  
The implants were placed in 10 ml phosphate buffer (pH 7.4, 37 °C) 
containing lysozyme enzyme (1 mg/ml). The PBS was changed for 
all the samples every day. Implants were taken out at 7, 14, 21 and 
28 d, washed with distilled water and air-dried for 72 h. The 
resulting dry weights were recorded. The mass loss of the samples 
was determined by gravimetry. 
Stability studies  
The stability protocol was based on the International Conference on 
Harmonisation (ICH) ‘Q1A (R2
Circular dichroism spectroscopy 
)’ guidelines. The implants were 
stored at 25 °±2 °C and 60±5 % RH for and at 5 °±3 ° C which is the 
accelerated storage temperature and long term storage 
temperatures respectively, for products intended to be refrigerated. 
Stability studies were performed for e formulation F2. The stability 
testing of samples was carried out at 0, 60, 120 and 180 d under 
long-term storage conditions. For accelerated conditions, the 
samples were assayed every 10 d for 30 d. 
Circular dichroism (CD) spectra were obtained with a Jasco J-810 
spectropolarimeter (Japan) equipped with a Pelltier temperature 
controller. Spectra were collected at 20°C using a 0.1 cm cell over 
the wavelength range of 200–270 nm. A resolution of 0.1 nm and 
scanning speed of 10 nm/min with a 2 s response time were 
employed. Each spectrum obtained represents an average of three 
consecutive scans. Noise reduction, blank buffer subtraction, and 
data analysis were performed using standard analysis and 
temperature/wavelength analysis programs (Jasco). Secondary 
structure content was estimated employing CDPro software with 
data in the range of 200–240 nm using the basis 4 and 7 programs 
for input data. Loaded implants containing insulin were dialyzed 
against water at 4 °C for 24 h before analysis by CD. Standard insulin 
solutions were prepared at 0.1 mg/ml in 10 mmol PBS. 
RESULTS AND DISCUSSION 
Content uniformity, potency and purity of insulin in implants 
The disc implants were 48±0.58 mg and had a thickness 851±8.9 
µm. The insulin content in the implants was 9.86±0.10 mg. The 
potency of insulin extracted from the implants was 27.11±0.75 
U/mg or 95.12±2.61 % of the control insulin. There was no 
significant difference (p<0.001) in potency or purity of the insulin 
extracted from implants compared to that of standard insulin. In 
addition, after storage at 2–8 °C for 6 mo, insulin in the implants 
manifested the same potency and purity as the initial preparation.  
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Primarily three mechanisms could be responsible for the release of 
drugs from the hydrogels: swelling, diffusion and degradation. Upon 
exposure to an aqueous media, first, the polymer swells due to the 
uptake of the water. The rate of water uptake by the implant 
depends on the hydrophobicity of the polymer. Second, when the 
implant swells, the encapsulated drug is released by diffusion 
through the pores formed due to swelling. The third mechanism, 
which involves degradation of the polymer matrix, would occur 
under in vivo conditions as a result of enzyme activity.  
The effect of crosslinking agents on the swell ability of the polymer 
could be demonstrated by the diffusion coefficient of water in the 
implant system. Moreover, the rate of drug delivery from an implant 
also depends on the rate of diffusion of the waterfront into the 
device. It is known that the greater the molecular size/weight of the 
drug, the greater is the sensitivity of the diffusion coefficient to 
changes in crosslink density. Insulin is regarded as a 
macromolecular peptide whose release from the implant apparently 
depends on the diffusion coefficient of water in the device as well as 
on the swellability of the polymer.  
The swelling degree of the implants was found to be in the range of 
1.07-1.56. The Berens–Hopfenberg differential equation 
Mt
M∞
= {1 − A exp(K2t)} was fitted to the data obtained from the 
swelling studies to assess the overall kinetics governing the swelling. 
In this equation, Mt is the swelling at time t and M∞  is the 
equilibrium swelling. In this studies, the constants A and k2 were 
calculated from the slopes and intercepts of the plot of log(1-
Mt/M∞) versus time t at times later than those corresponding to 
Mt/M∞=0.6. The calculated values of A and k2 are listed in table 2. 
The values of A were in the range of 0.17-0.43 indicating Fickian 
diffusion. The diffusion coefficient for water transport was 
calculated by plotting log [π2/8(1-Mt/M∞)] versus t for 
0.4<Mt/M∞<1 (Eq. 2). The slope of the plot was π2D/2.303×4δ² from 
which the diffusion coefficient D was calculated (table 2). The 
diffusion coefficient of water through the implant was found to 
depend on the CaCl2
The maximum diffusion coefficient was observed with implants 
prepared with a CaCl
 concentration.  
2 concentration of 0.05% w/v. When the cross 
linker concentration was increased from 0.05% w/v (F1) to 0.1% 
w/v (F2) the diffusion coefficient of water through the implant 
decreased from 2.08×10-4to 1.73×10-4 cm2/sec and from 2.28×10-6to 
2.18×10-6 cm2
 
/sec for F3 and F4, respectively. This may be explained 
by the fact that on increasing the crosslinker content there is a 
prominent decrease in the free volumes available between the 
chains of the macromolecular network and thus the swelling of 
implant decreases. The crosslink density of hydrogels provides a 
restricted aqueous environment for diffusional migration of the 
peptide, by controlling both the degree of hydration and the 
permeability of hydrogels to protein [14]. 
Table 2: Parameters A, k2
Formulations 
 and diffusion coefficient of water from swelling studies 
A k2×10-3(min-1 R) D (cm2 2/sec) 
F1 0.25 3.1 0.992 2.08× 10-4 
F2 0.17 2.6 0.973 1.73× 10
F3 
-4 
0.43 5.3 0.986 2.28× 10
F4 
-6 
0.28 6.5 0.991 2.18× 10-6 
(n=3) mean±SD 
 
Scanning electron microscopy studies 
The scanning electron microscopy studies of the PVA/gellan implants 
(fig. 1 and 2) clearly showed a difference in the microstructure of the 
swollen and dry state of the cross section of the implant. This provides 
structural proof for the hypotheses we made regarding the release of 
insulin from the implant systems due to swelling of the polymer. 
In vitro release studies 
The formulation F1 showed the complete release of insulin in 16 d, 
while for F2, F3 and F4 complete release of insulin were seen in 19, 13 
and 15 d respectively. Obviously, this infers that the release depends 
on the PVA content and CaCl2 concentration in the formulation. The 
increase in CaCl2 retarded the rate of insulin release whereas the 
increase in PVA content leads to rapid release of insulin. The in vitro 
release of the various formulations is shown in the fig. 3. The fraction 
of insulin released (Mt/M∞) less than 0.6 was fitted to the equation 
Mt/M∞=ktn, where Mt is the insulin released at time t, M∞ is the 
maximum insulin released, k is the characteristic constant of the 
polymer, and n is the characteristic exponent describing the 
penetration mechanism. For planar geometry, a value of n=0.5 
indicates a Fickian diffusion mechanism, 0.5<n<1.0 indicates non-
Fickian or anomalous transport, and n=1 implies case II (relaxation 
controlled) transport. The constants n and k were calculated from the 
slope and intercepts of the plots of log (Mt/M∞) versus log t, 
respectively. The calculated value of n was 0.86-0.89, which indicated 
that the release of insulin followed non-Fickian or anomalous 
transport. This suggests that the release of insulin from the implant 
was controlled by swelling of the matrix due to water penetration into 
the implant. 
The diffusion coefficient of insulin (molecular weight 5900, 
hydrodynamic radius 16A°) was calculated using Eqs.2 and 3 (table 3). 
The diffusion coefficient of insulin decreased when the 
concentration of CaCl2
 
Fig. 1: SEM pictures of cross-section of implant (F2) before swelling 
 
 increased due to an increase in the crosslink 
density, which compacts the network. It is likely that the increase in 
the compactness restricts the mobility of the network chains (chain 
relaxation) and impedes diffusion of insulin from the implant. 
 
Fig. 2: SEM pictures of cross-section of implant after swelling 
(F2) in a buffer medium over a period of 240 min
Table 3: Diffusion coefficients of insulin through the implant 
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Formulations Diffusion coefficient (× 10-5 cm2/sec) 
Early stages Later stages 
F1 6.65 0.92 
F2 3.33 0.69 
F3 8.73 1.10 




Fig. 3: In vitro release studies of insulin implants in PBS (7.4) at 
37 °C, n=3, Data presented as mean±SD 
 
Enzyme-mediated degradation studies 
It is known that chitosans with block structures and lower degrees 
of deacetylation (<75%) are more readily degraded due to the 
presence of blocks of glucosamine moieties containing acetyl groups 
that serve as a substrate for lysozyme. In the present study, we used 
chitosan (75-85% deacetylated) that has been shown to degrade in 
vivo in about 6 mo [15]. 
The in vitro degradation studies showed that there was a significant 
weight loss of the implants when placed in phosphate buffer 
solution pH 7.4 containing lysozyme indicating the degradation of 
the implants. The degradation studies were carried out for 4 w and 
the % weight loss of the implants was found to be 20.8±2.0 (fig. 4). 
 
 
Fig. 4: Degradation studies of the implants F1, F2, F3 and F4, 
n=3, Data presented as mean±SD 
 
Stability studies  
Observations under long-term storage conditions and accelerated 
conditions are shown in the fig. 5 and 6. The insulin content in the 
formulation in long-term storage conditions and accelerated storage 
conditions along with 95% confidence limits were plotted 
(sigmaplot version 9.0). When the implants were stored under 
long-term storage conditions the insulin content in formulation F2 
was found to be 9.47±0.06 mg (94.7% of the initial content) after six 
mo. Under accelerated conditions, the insulin content was 7.50±0.23 
mg (75% of the initial content). These results suggest that at any 
time (either during transit or storage) the insulin implants should be 
stored at refrigerator temperatures.  
 
 
Fig. 5: Insulin content in the implants (F2) when stored at 5 °±3 
° C for 180 d, n=3, Data presented as mean±SD 
 
 
Fig. 6: Insulin content in the implants (F2) when stored at 25±2 
°C and 65%RH±5%RH for 30 d. n=3, Data presented as 
mean±SD 
 
Circular dichroism spectroscopy 
The CD spectra of control insulin and the insulin extracted from 
the implant (F2) are shown in fig. 7.  
Compared with the CD spectrum of control insulin, no significant 
change was observed in that of the insulin extracted from the 
implant in the PBS solution, indicating that the conformation of 


























Fig. 7: The CD spectra 
 
CONCLUSION 
These studies provide validity for the potential utility of chitosan-
PVA-gellan implant systems for the delivery of insulin. The studies 
also demonstrate that insulin maintained its integrity within the 
implant system. Implants showed the complete release of insulin in 
19 d and the release of insulin from the implants depended on the 
amount of CaCl2
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